AI Article Synopsis
- Atherosclerotic cardiovascular disease is a significant issue for those with chronic kidney disease (CKD), as CKD leads to changes in smooth muscle cells (SMCs) that may promote atherosclerosis.
- Researchers tested whether uremia (a condition resulting from CKD) increases neointima formation (a thickening of the arterial wall) after vascular injury in mice, comparing normal and Apoe knockout mice.
- However, the study found that uremia did not enhance neointima formation or alter SMC marker gene expression in the injured arteries, suggesting that uremia affects SMCs differently depending on the vascular region.
Article Abstract
Atherosclerotic cardiovascular disease is a major complication of chronic kidney disease (CKD). CKD leads to uremia, which modulates the phenotype of aortic smooth muscle cells (SMCs). Phenotypic modulation of SMCs plays a key role in accelerating atherosclerosis. We investigated the hypothesis that uremia potentiates neointima formation in response to vascular injury in mice. Carotid wire injury was performed on C57BL/6 wt and apolipoprotein E knockout (Apoe ) mice two weeks after induction of uremia by 5/6 nephrectomy. Wire injury led to neointima formation and downregulation of genes encoding classical SMC markers (i.e., myocardin, α-smooth muscle actin, SM22-alpha, and smooth muscle myosin heavy chain) in both wt and Apoe mice. Contrary to our expectations, uremia did not potentiate neointima formation, nor did it affect intimal lesion composition as judged from magnetic resonance imaging and histological analyses. Also, there was no effect of uremia on SMC marker gene expression in the injured carotid arteries, suggesting that there may be different effects of uremia on SMCs in different vascular beds. In conclusion, uremia does not accelerate neointima formation in response to wire injury of the carotid artery in mice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529519 | PMC |
| http://dx.doi.org/10.1038/s41598-017-06816-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adventitial Injection of HA/SA Hydrogel Loaded With IL-33 Antibody Decreases Neointimal Hyperplasia.
J Surg Res
December 2024
Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Introduction: Neointimal hyperplasia is one of the persistent complications after vascular interventions, and is the major cause of treatment failure. Interleukin-33 (IL-33) emerges as a crucial factor in many biological processes and plays an important role in vascular diseases. Adventitial injection is catching attention for its effectiveness and fewer side effects.
View Article and Find Full Text PDFColchicine reduces neointima formation and VSMC phenotype transition by modulating SRF-MYOCD activation and autophagy.
Acta Pharmacol Sin
December 2024
Anhui Provincial International Science and Technology Cooperation Base for Major Metabolic Diseases and Nutritional Interventions, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230601, China.
Vascular smooth muscle cell (VSMC) phenotype transformation significantly contributes to vascular intimal hyperplasia. However, effective preventive and therapeutic measures are lacking. Colchicine, a binary alkaloid derived from Colchicum autumnale, is traditionally used for treating inflammatory diseases.
View Article and Find Full Text PDFFhl1, a new spatially specific protein, regulates vein graft neointimal hyperplasia.
Clin Transl Med
December 2024
Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Article Synopsis
- Vein grafts are critical for treating coronary artery disease, but neointimal hyperplasia (NIH) poses a significant challenge to their long-term success, with current identification and intervention methods being insufficient.
- Researchers conducted a study using rats to observe the NIH development process after vein grafting while examining gene expression and specific markers related to NIH through various analytical methods.
- The results showed that repair cells from outside the graft contribute significantly to NIH, with the protein Fhl1 playing a protective role against inflammation and cell proliferation, offering potential targets for improved treatments.
Investigating the efficacy of uncrosslinked porcine collagen coated vascular grafts for neointima formation and endothelialization.
Front Bioeng Biotechnol
November 2024
Division of Cardiovascular Surgery, Cardiac and Vascular Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
Introduction: This study evaluates the efficacy of uncrosslinked porcine collagen coated vascular grafts (UPCCVG) in facilitating neointima formation and endothelialization.
Methods: Prior to coating, the uncrosslinked porcine collagen underwent comprehensive characterization employing SDS-PAGE, image analysis, circular dichroism and immunogenicity. The PET substrate of the vascular graft was coated with collagen solution utilizing the dip-coating method.
PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy.
Biochem Biophys Res Commun
January 2025
Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, Hebei, China; Hebei Key Laboratory of Heart and Metabolism, Shijiazhuang, 050031, Hebei, China. Electronic address:
We aim to explore the impact of Proprotein convertase subtilisin-kexin type 9 (PCSK9) and its inhibitor evolocumab on neointimal hyperplasia. Wild type and PCSK9 knockout (PCSK9) mice were subjected to ligation of the common carotid artery, with or without subcutaneous injection of evolocumab. Mouse aortic vascular smooth muscle (MOVAS) cells were pretreated with evolocumab or under siRNA-mediated suppression of PCSK9, and then exposed to platelet-derived growth factor type BB(PDGF-BB), a major promoter of MOVAS transformation to a proliferative phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!